AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AMPLIA THERAPEUTICS LTD

0.120

+0.0054.35%

Volume:611.39K

Turnover:74.00K

Market Cap:61.57M

PE:-5.95

High:0.125

Open:0.120

Low:0.120

Close:0.115

52wk High:0.425

52wk Low:0.049

Shares:513.07M

Float Shares:351.32M

Volume Ratio:1.25

T/O Rate:0.17%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.020

EPS(LYR):-0.021

ROE:-28.49%

ROA:-17.71%

PB:1.43

PE(LYR):-5.61

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Amplia Therapeutics Secures Key US Patent for Narmafotinib, Extending Protection to 2040

Amplia Therapeutics Produces Around 13 Kilograms of Cancer Treatment Drug Candidate For Use in Clinical Trials, Shares Jump 7%

MT Newswires Live

Ribomic Files Patent for Anti-Autotaxin Aptamer RBM-006

MT Newswires Live

Amplia Therapeutics Reports Promising Phase 2a Trial Results for Narmafotinib in Pancreatic Cancer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ATX.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ATX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ATX.AU\",,,,,undefined,":{"symbol":"ATX.AU","market":"AU","secType":"STK","nameCN":"AMPLIA THERAPEUTICS LTD","latestPrice":0.12,"timestamp":1770700320000,"preClose":0.115,"halted":0,"volume":611385,"delay":0,"changeRate":0.04347826086956513,"nameEN":"AMPLIA THERAPEUTICS LTD","floatShares":351321835,"shares":513071629,"eps":-0.020164,"marketStatus":"Not Yet Opened","change":0.005,"latestTime":"02-10 16:12:00 AEDT","open":0.12,"high":0.125,"low":0.12,"amount":74000,"amplitude":0.043478,"askPrice":0.13,"askSize":50000,"bidPrice":0.12,"bidSize":20000,"shortable":3,"etf":0,"ttmEps":-0.020164,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1770764400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.115,"openAndCloseTimeList":[[1770678000000,1770699600000]],"volumeRatio":1.249171,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ATX.AU\",,,,,undefined,":{"symbol":"ATX.AU","floatShares":351321835,"roa":"-17.71%","roe":"-28.49%","lyrEps":-0.021392,"volumeRatio":1.249171,"shares":513071629,"dividePrice":0,"high":0.125,"amplitude":0.043478,"preClose":0.115,"low":0.12,"week52Low":0.049,"pbRate":"1.43","psRate":"12.30","week52High":0.425,"institutionHeld":0,"latestPrice":0.12,"committee":-0.428571,"eps":-0.020164,"divideRate":0,"volume":611385,"delay":0,"ttmEps":-0.020164,"open":0.12,"prevYearClose":0.15,"prevWeekClose":0.12,"prevMonthClose":0.13,"prevQuarterClose":0.15,"fiveDayClose":0.13,"twentyDayClose":0.17,"sixtyDayClose":0.13,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATX.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-04-18","symbol":"ATX.AU","defaultRemindTime":1713398400000,"type":"split","dateTimestamp":1713362400000,"forFactor":971896,"toFactor":1000000,"ratio":0.971896}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATX.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2607046551","title":"Amplia Therapeutics Secures Key US Patent for Narmafotinib, Extending Protection to 2040","url":"https://stock-news.laohu8.com/highlight/detail?id=2607046551","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607046551?lang=en_us&edition=fundamental","pubTime":"2026-01-30 21:45","pubTimestamp":1769780710,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics Ltd. announced that a key patent covering the specific salt and crystal form of narmafotinib used in clinical trials has been granted by the US Patent and Trademark Office. The patent extends protection of the developed form of narmafotinib out to at least 2040 in the US and other jurisdictions where the patent has also been granted, including Europe, Japan, India, and Australia.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amplia Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire  on January 30, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nNDL9lL1VJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BKPKM429.USD","SG9999014005.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD","LU2210150020.SGD","NDAQ","SG9999014039.USD","BK7067","BK4585","SG9999014021.USD","LU2210149790.SGD","BK4112","SG9999014013.SGD","ATX.AU","BK4588"],"gpt_icon":0},{"id":"2605430773","title":"Amplia Therapeutics Produces Around 13 Kilograms of Cancer Treatment Drug Candidate For Use in Clinical Trials, Shares Jump 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605430773","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605430773?lang=en_us&edition=fundamental","pubTime":"2026-01-22 09:41","pubTimestamp":1769046106,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics (ASX:ATX) produced around 13 kilograms of its narmafotinib drug candidate for the treatment of cancer to the required purity and quality specifications after the completion of a la","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4139","BK4007","ATX.AU","BK4539","BK7067"],"gpt_icon":0},{"id":"2603986426","title":"Ribomic Files Patent for Anti-Autotaxin Aptamer RBM-006","url":"https://stock-news.laohu8.com/highlight/detail?id=2603986426","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603986426?lang=en_us&edition=fundamental","pubTime":"2026-01-14 15:44","pubTimestamp":1768376683,"startTime":"0","endTime":"0","summary":"Ribomic  has filed a new substance patent for RBM-006, a highly active anti-autotaxin  aptamer, highlighting its therapeutic potential in a mouse model of diabetic retinopathy, according to a Wednesday filing on the Tokyo Stock Exchange.RBM-006, developed in collaboration with the University of Tokyo's Department of Ophthalmology, demonstrated significant suppression of retinal hemorrhage in mice. The aptamer, which surpasses existing anti-ATX candidates in activity and has a shorter chain length, is being investigated for ophthalmic conditions including glaucoma and age-related macular degeneration.With anti-VEGF therapies ineffective in over half of patients, Ribomic sees RBM-006 as a potential alternative treatment. The company plans to explore early commercialization through partnerships and continues to fund development as scheduled.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ATX.AU","BK7067"],"gpt_icon":0},{"id":"2602543397","title":"Amplia Therapeutics Reports Promising Phase 2a Trial Results for Narmafotinib in Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2602543397","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602543397?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:45","pubTimestamp":1768225509,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics Ltd. has announced the presentation of interim data from its ongoing Phase 2a ACCENT trial in metastatic pancreatic cancer at the 2026 ASCO Gastrointestinal Cancer Symposium. The trial evaluates the efficacy and safety of Amplia’s FAK inhibitor, narmafotinib, in combination with standard chemotherapy. The updated data show a progression-free survival of 7.7 months compared to 5.5 months for gemcitabine and Abraxane alone. The overall response rate is reported at 35%, increasing to 42% when including unconfirmed responses. Narmafotinib was found to be well tolerated, with an adverse effect profile similar to chemotherapy alone. The results were shared in a poster presentation and a copy is available on the company’s website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL2TLXkw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","BK4588","BK4112","IE00B3QW5Z07.USD","LU0314104364.USD","LU2095319765.USD","NDAQ","BK7067","SG9999014039.USD","SG9999014021.USD","LU2210149790.SGD","SG9999014013.SGD","BK4585","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210150020.SGD","ATX.AU"],"gpt_icon":0}],"pageSize":4,"totalPage":6,"pageCount":1,"totalSize":24,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ATX.AU\",params:#limit:6,delay:true,,,undefined,":[]}}